Category: Press Release

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 13, 2018– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the full year ended December 31, 2017 and provided a business update. “Last year was one of major progress for AVEO, with highlights including the first commercial launch of tivozanib (FOTIVDA®); the completion of the enrollment for TIVO-3, our U.S. registration study; the receipt of promising

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 6, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conferencein Boston on Tuesday, March 13, 2018 at 10:40 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast

Download PDF Recommendation Triggers $2M Milestone Payment from EUSA to AVEO CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 12, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that the United Kingdom’s National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending FOTIVDA® (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). In the European Union, Norway and Iceland, tivozanib is indicated

Download PDF Data Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Feb. 10, 2018– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced the presentation of preliminary results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 7, 2018– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 1, 2018– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of John H. Johnson to the Company’s Board of Directors. Mr. Johnson brings to AVEO over three decades of experience in the biotechnology and pharmaceuticals industries, having held commercial and executive management roles at leading global corporations that have a focus on oncology, including Johnson &

Download PDF Poster Presentation Delivered at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 19, 2018– AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from a multicenter, Phase 1b/2 study of FOTIVDA® (tivozanib), a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in patients with advanced,

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 4, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at 11:30 a.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of

Download PDF Provides Approximately $12.1M in Additional Cash Flow Over 2018-19 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 2, 2018– AVEO Oncology (NASDAQ:AVEO) today announced that it has completed the refinancing of its existing $20.0 million debt facility with Hercules Capital, Inc. and its affiliates, the terms of which enable approximately an additional $12.1 million in cash flow over 2018 and 2019, when compared to the prior loan. The

Download PDF – Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial;Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018- – Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 7, 2017– AVEO Oncology (NASDAQ:AVEO) today announced clinical updates for two of its oncology programs: FOTIVDA® (tivozanib), the Company’s